Interferon-Gamma and Donor Cells for Relapsed Leukemia After Transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that came back after a stem cell transplant.
- Your cancer shows signs of coming back—like having at least 5% abnormal cells in bone marrow, or certain DNA changes detected by special tests.
- You are in generally good health (able to be up and about for at least half the day).
- A supply of donor white blood cells is available, or your original donor can donate more.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving donor immune cells earlier or later after a stem cell transplant helps prevent relapse in people with tough-to-treat leukemia or MDS. Participants must be in remission one month after transplant.
This study tests whether giving extra immune cells (called DLI) before or after a stem cell transplant can help prevent or treat leukemia relapse. These cells come from the same family member who donated your transplant, and the study also asks the donor to do some exercise sessions beforehand.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This study tests whether a medication called IFN-α can help prevent the blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancers who are at high risk of relapse.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
This trial tests whether infusing donor immune cells after a stem cell transplant can help treat AML or MDS. It involves donating and receiving a specific type of immune-cell infusion, with safety checks around the donor’s procedure.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.